Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 61, Issue 2, 2007, Pages 174-180

  Sakumoto, Noboru ^a   Kondo, Tsuyoshi ^a   Mihara, Kazuo ^a   Suzuki, Akihito ^b   Yasui Furukori, Norio ^c  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

141C Ins Del polymorphism; Antidopaminergic agents; Dopamine D2 receptor; Prediction of response; TaqI A polymorphism

Indexed keywords

BIPERIDEN; BROMPERIDOL; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EMONAPRIDE; FLUNITRAZEPAM; HALOPERIDOL; SENNOSIDE; BIOLOGICAL MARKER; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENOTYPE; HUMAN; INSOMNIA; MALE; PATIENT COMPLIANCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; RECEPTOR GENE; SCHIZOPHRENIA; TREATMENT DURATION; BLOOD; GENETIC POLYMORPHISM; GENETICS; PREDICTION AND FORECASTING; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HALOPERIDOL; HUMANS; MALE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33847637647     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2007.01633.x     Document Type: Article

References (32)

1. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J. Clin. Psychiatry 2001; 62: 757-771.
2. Seeman P. Dopamine receptors. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1995; 295-302.
3. Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin. Pharmacokinet. 1998; 34: 227-263.
4. 2 receptors from plasma levels. Psychopharmacology 2000; 149: 1-5.
5. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry 1992; 149: 500-505.
6. 2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am. J. Hum. Genet. 1989; 45: 778-785.
7. 2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 1998; 1: 33-45.
8. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-484.
9. 2 receptor availability in healthy volunteers. Mol. Psychiatry 1998; 3: 256-260.
10. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 1997; 6: 577-582.
11. Jönsson EG, Nöthen MM, Grünhage F et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999; 4: 290-296.
12. 2 receptor polymorphism at the Taq1A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000; 10: 335-341.
13. 2 receptor gene. Am. J. Psychiatry 2001; 158: 802-804.
14. 2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11: 545-550.
15. Wu S, Xing Q, Gao R et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci. Lett. 2005; 376: 1-4.
16. 2 receptor gene and clozapine response. Schizophr. Res. 1999; 36: 92-93.
17. 2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 921-926.
18. 3H] raclopride for dopamine D-2 receptor binding to rat striatum. Eur. J. Pharmacol. 1989; 173: 177-182.
19. Schotte A, Bonaventure P, Janssen PFM, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J. Pharmacol. 1995; 69: 399-412.
20. Otani K, Kondo T, Yasui N et al. Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients. Hum. Psychopharmacol. 1997; 12: 591-594.
21. Yasui N, Kondo T, Otani K et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol. Toxicol. 1998; 82: 153-156.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV). American Psychiatric Association, Washington, DC, 1994.
23. Benfield P, Ward A, Clark BG, Jue SG. Bromperidol.A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs 1988; 35: 670-684.
24. Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotropic drugs. Part II. Dose equivalence of orally administered neuroleptics (in Japanese). Jpn J. Clin. Psychopharmacol. 1998; 1: 215-219.
25. Bech P, Kastrup M, Rafaelsen OJ. Mini-conpedium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand. 1986; 73 (Suppl. 326): 1-37.
26. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987; 76 (Suppl. 334): 11-100.
27. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum. Mol. Genet. 1993; 2: 2197.
28. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J. Chromatogr. 1989; 495: 227-234.
29. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Ohtani K, Kaneko S. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J. Chromatogr. B 1998; 714: 293-298.
30. Steel RM, Johnstone EC. Should the treatment of schizophrenia include old antipsychotic drugs? Curr. Psychiat. Rep. 2000; 2: 404-409.
31. 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology 1997; 131: 148-152.
32. Van Putten T, Marder SR, May PRA, Poland RE, O'Brien RP. Plasma levels of haloperidol and clinical response. Psychopharmacol. Bull. 1985; 21: 69-72.